Payment overview · 2025
General Payments
$431.23
18 reported records · 9 companies
Healthcare provider profile · identity verified
Peter Yang Ma, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · ARCADIA, CA · NPI 1902831019
Verified facts
What the public records show
CMS Open Payments records show Peter Yang Ma, M.D. received $431.23 in general payments during 2025 across 18 reported records.
PFIZER INC. accounted for 22.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Kerendia, Paxlovid, Trelegy Ellipta.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 236 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 236 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 126 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $96.27 | 22.3% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $69.73 | 16.2% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $61.59 | 14.3% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $46.17 | 10.7% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $43.50 | 10.1% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $41.53 | 9.6% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $27.27 | 6.3% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $25.33 | 5.9% | 1 | 2025 |
| VIVUS LLC | Unresolved — no canonical attribution shown | $19.84 | 4.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $431.23 | 18 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $69.73 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $60.27 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $57.29 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $57.29 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $57.29 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $46.17 | 2 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $38.98 | 2 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $34.23 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $27.36 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $27.27 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $27.27 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $25.33 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $24.76 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $24.76 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $24.20 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $21.97 | 1 | 2025 |
Source payment records
|
|||||
| PANCREAZE Normalized: pancreaze |
Drug | VIVUS LLC | $19.84 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 236 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 13 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
78 | 59 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
53 | 12 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
236 | 45 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
236 | 45 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
126 | 28 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
13 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 1295 | 277 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 1273 | 313 |
| Atorvastatin Calcium | Atorvastatin Calcium | 982 | 259 |
| Losartan Potassium | Losartan Potassium | 926 | 252 |
| Metformin Hcl | Metformin Hcl | 741 | 179 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 523 | 117 |
| Tamsulosin Hcl | Tamsulosin Hcl | 506 | 117 |
| Omeprazole | Omeprazole | 486 | 140 |
| Metoprolol Succinate | Metoprolol Succinate | 468 | 112 |
| Levothyroxine Sodium | Levothyroxine Sodium | 417 | 85 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 288 | 92 |
| Glimepiride | Glimepiride | 240 | 49 |
| Jardiance | Empagliflozin | 236 | 45 |
| Bethanechol Chloride | Bethanechol Chloride | 227 | 61 |
| Finasteride | Finasteride | 221 | 42 |
| Escitalopram Oxalate | Escitalopram Oxalate | 192 | 42 |
| Famotidine | Famotidine | 189 | 46 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 189 | 107 |
| Zolpidem Tartrate | Zolpidem Tartrate | 185 | 65 |
| Alendronate Sodium | Alendronate Sodium | 180 | 55 |
| Clopidogrel | Clopidogrel Bisulfate | 172 | 33 |
| Metformin Hcl Er | Metformin Hcl | 165 | 38 |
| Vascepa | Icosapent Ethyl | 164 | 37 |
| Fenofibrate | Fenofibrate Nanocrystallized | 162 | 34 |
| Montelukast Sodium | Montelukast Sodium | 154 | 59 |
| Azithromycin | Azithromycin | 153 | 121 |
| Donepezil Hcl | Donepezil Hcl | 153 | 28 |
| Januvia | Sitagliptin Phosphate | 152 | 28 |
| Raloxifene Hcl | Raloxifene Hcl | 147 | 42 |
| Icosapent Ethyl | Icosapent Ethyl | 143 | 34 |
| Fluticasone Propionate | Fluticasone Propionate | 132 | 61 |
| Eliquis | Apixaban | 126 | 28 |
| Irbesartan | Irbesartan | 118 | 20 |
| Cyclosporine | Cyclosporine | 117 | 24 |
| Azelastine Hcl | Azelastine Hcl | 116 | 20 |
| Lisinopril | Lisinopril | 114 | 26 |
| Allopurinol | Allopurinol | 103 | 26 |
| Simvastatin | Simvastatin | 102 | 24 |
| Trazodone Hcl | Trazodone Hcl | 99 | 25 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 94 | 28 |
| Ezetimibe | Ezetimibe | 92 | 19 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 92 | 26 |
| Carvedilol | Carvedilol | 91 | 24 |
| Diclofenac Sodium | Diclofenac Sodium | 91 | 45 |
| Gabapentin | Gabapentin | 88 | 25 |
| Glipizide | Glipizide | 84 | 14 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 82 | 24 |
| Hydralazine Hcl | Hydralazine Hcl | 80 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 79 | 16 |
| Prolia | Denosumab | 78 | 59 |
| Atenolol | Atenolol | 77 | 23 |
| Meloxicam | Meloxicam | 75 | 31 |
| Celecoxib | Celecoxib | 74 | 29 |
| Pantoprazole Sodium | Pantoprazole Sodium | 73 | 17 |
| Baclofen | Baclofen | 72 | 38 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 72 | 26 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 68 | 48 |
| Valsartan | Valsartan | 66 | 16 |
| Dutasteride | Dutasteride | 60 | 11 |
| Nifedipine Er | Nifedipine | 59 | 11 |
| Amoxicillin | Amoxicillin | 58 | 51 |
| Hydrochlorothiazide | Hydrochlorothiazide | 58 | 28 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 57 | 20 |
| Temazepam | Temazepam | 57 | suppressed |
| Memantine Hcl | Memantine Hcl | 56 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 53 | 12 |
| Rybelsus | Semaglutide | 53 | 13 |
| Creon | Lipase/Protease/Amylase | 52 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 51 | 25 |
| Clonidine | Clonidine | 51 | suppressed |
| Ciclopirox | Ciclopirox | 50 | 24 |
| Clonidine Hcl | Clonidine Hcl | 50 | 19 |
| Dexlansoprazole Dr | Dexlansoprazole | 49 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 49 | 16 |
| Fenofibrate | Fenofibrate,micronized | 48 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 48 | 13 |
| Meclizine Hcl | Meclizine Hcl | 47 | 36 |
| Restasis | Cyclosporine | 46 | 14 |
| Cephalexin | Cephalexin | 45 | 39 |
| Lorazepam | Lorazepam | 44 | 17 |
| Pioglitazone Hcl | Pioglitazone Hcl | 44 | 14 |
| Nitroglycerin | Nitroglycerin | 43 | 29 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 41 | 11 |
| Sertraline Hcl | Sertraline Hcl | 41 | suppressed |
| Gemfibrozil | Gemfibrozil | 40 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 40 | 12 |
| Terazosin Hcl | Terazosin Hcl | 40 | suppressed |
| Mirtazapine | Mirtazapine | 39 | suppressed |
| Tradjenta | Linagliptin | 38 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 37 | 26 |
| Benazepril Hcl | Benazepril Hcl | 35 | suppressed |
| Folic Acid | Folic Acid | 35 | 11 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 35 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 34 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 34 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 33 | 16 |
| Telmisartan | Telmisartan | 32 | suppressed |
| Calcitriol | Calcitriol | 31 | suppressed |
| Fluconazole | Fluconazole | 31 | 24 |
| Fluocinonide | Fluocinonide | 30 | 16 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 29 | suppressed |
| Ranolazine Er | Ranolazine | 28 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 26 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 26 | suppressed |
| Benicar | Olmesartan Medoxomil | 25 | suppressed |
| Linzess | Linaclotide | 25 | suppressed |
| Entecavir | Entecavir | 24 | suppressed |
| Acyclovir | Acyclovir | 23 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 23 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 23 | suppressed |
| Fenofibrate | Fenofibrate | 22 | suppressed |
| Kerendia | Finerenone | 22 | suppressed |
| Xarelto | Rivaroxaban | 22 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 21 | suppressed |
| Nystatin | Nystatin | 21 | 13 |
| Colchicine | Colchicine | 20 | 12 |
| Hydrocortisone | Hydrocortisone | 20 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 20 | suppressed |
| Furosemide | Furosemide | 19 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 19 | suppressed |
| Restasis Multidose | Cyclosporine | 19 | suppressed |
| Spironolactone | Spironolactone | 19 | suppressed |
| Febuxostat | Febuxostat | 18 | suppressed |
| Metronidazole | Metronidazole | 18 | 17 |
| Latanoprost | Latanoprost | 17 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 17 | suppressed |
| Methylprednisolone | Methylprednisolone | 17 | 16 |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 16 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 15 | suppressed |
| Repaglinide | Repaglinide | 15 | suppressed |
| Vemlidy | Tenofovir Alafenamide | 15 | suppressed |
| Erythromycin | Erythromycin Base | 14 | suppressed |
| Methimazole | Methimazole | 14 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 14 | 11 |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 13 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 13 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Lidocaine | Lidocaine | 13 | suppressed |
| Olanzapine | Olanzapine | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Clotrimazole | Clotrimazole | 12 | suppressed |
| Donepezil Hcl Odt | Donepezil Hcl | 12 | suppressed |
| Estazolam | Estazolam | 12 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 12 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | 12 |
| Clonazepam | Clonazepam | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 11 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 11 | suppressed |
| Repatha Sureclick | Evolocumab | 11 | suppressed |
| Trulicity | Dulaglutide | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $431.23 · 18 records | PFIZER INC. | ABRYSVO, AREXVY, BREZTRI, CAPVAXIVE, COMIRNATY, EVENITY, GARDASIL 9, JARDIANCE, KRYSTEXXA, Kerendia, MOUNJARO, PANCREAZE, PAXLOVID, PREVNAR 20, SHINGRIX, TRELEGY ELLIPTA, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error